Skip to content
CompoundSci
All peptides
Research vial labelled Melanotan II, a Melanocortin and sexual peptide studied in preclinical and clinical literature

Melanotan II

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

Melanocortin agonism has real off-target effects. Read the safety section first.

General profile

Class
Melanocortin and sexual
Evidence
Early or preclinical only
Studied dose range
250–500 mcg
Frequency in protocols
Daily loading, then 2–3× weekly
Route
Subcutaneous
Half life
~1 hour
Reconstitution
2 mL bacteriostatic water per 10 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the evening window

Daily during loading, then two to three times weekly

Nausea and flushing peak in the first hour or two, so evening dosing lets that pass during sleep. Melanocortin agonism has genuine off-target effects, read the safety literature first.

Reported cycle: 3 weeks on, 6 weeks off

Loading is short by design, then maintenance is spaced widely. This compound has the thinnest safety margin on the list.

Watch for: Any new or changing mole, nausea, flushing, spontaneous erections, and darkening that is uneven. Get a skin check before and after.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    Melanotan II + Melanotan I

    Never run both melanocortin agonists

    Same receptor family with overlapping pigmentation and cardiovascular effects. Melanotan II is the less selective of the two, so combining them adds side effects rather than pigment.

  • Hard stopTiming

    Melanotan II + PT-141

    Additive blood pressure and nausea

    Both are melanocortin agonists that transiently raise blood pressure and cause nausea. Together those effects stack in the same window.

  • Separate syringesSame day fine, same syringe not

    Melanotan II + BPC-157

    Keep Melanotan II alone in the barrel

    Melanotan II stays on its own even on a shared protocol day, and it reliably causes nausea, flushing and blood pressure changes in the first hours. If you introduce it next to anything else you cannot attribute a reaction.

  • Separate syringesSame day fine, same syringe not

    Melanotan II + TB-500

    Keep Melanotan II alone in the barrel

    Same rule: own draw, and introduce it at least a week apart from any other new compound so a reaction is readable.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Melanotan II fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature